Entropy Technologies LP Has $1.74 Million Stock Holdings in Haleon PLC Sponsored ADR (NYSE:HLN)

Key Points

• Entropy Technologies LP increased its holdings in Haleon PLC Sponsored ADR by 111.3% in the first quarter, owning 168,644 shares worth approximately $1.735 million.
• Several institutional investors, including Allspring Global Investments and Oppenheimer & Co., have also increased their stakes in Haleon, indicating growing confidence in the company.
• Haleon recently declared a semi-annual dividend of $0.0555 per share, a boost from its previous dividend, representing a yield of 190.0%.

Entropy Technologies LP boosted its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 111.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 168,644 shares of the company's stock after acquiring an additional 88,843 shares during the quarter. Entropy Technologies LP's holdings in Haleon were worth $1,735,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bartlett & CO. Wealth Management LLC grew its holdings in shares of Haleon by 135.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after acquiring an additional 1,491 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in Haleon during the first quarter valued at $29,000. Deutsche Bank AG increased its position in Haleon by 267.8% in the 1st quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock worth $32,000 after purchasing an additional 2,276 shares during the last quarter. FIL Ltd lifted its holdings in shares of Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after buying an additional 1,270 shares during the last quarter. Finally, Continuum Advisory LLC raised its position in Haleon by 152.4% during the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock valued at $49,000 after acquiring an additional 2,870 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Haleon stock traded up $0.02 during mid-day trading on Thursday, hitting $9.71. 6,544,855 shares of the company's stock traded hands, compared to its average volume of 13,079,159. The stock has a market cap of $43.59 billion, a price-to-earnings ratio of 24.89, a P/E/G ratio of 2.83 and a beta of 0.23. The firm has a 50 day simple moving average of $10.09 and a two-hundred day simple moving average of $10.20. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be issued a $0.0555 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a yield of 190.0%. This is a boost from Haleon's previous semi-annual dividend of $0.05. Haleon's payout ratio is presently 28.21%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Barclays reissued an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research note on Friday, May 9th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a research report on Tuesday, May 27th. Five analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Haleon presently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.